Literature DB >> 29874210

Everything but amyloid: new thinking prompts FDA revamp.

Eva von Schaper.   

Abstract

Year:  2018        PMID: 29874210     DOI: 10.1038/nbt0618-483

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Pivotal trials for β-secretase inhibitors in Alzheimer's.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2015-02       Impact factor: 54.908

2.  Genentech's Alzheimer's antibody trial to study disease prevention.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2012-08       Impact factor: 54.908

3.  The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Authors:  Jeff Sevigny; Ping Chiao; Thierry Bussière; Paul H Weinreb; Leslie Williams; Marcel Maier; Robert Dunstan; Stephen Salloway; Tianle Chen; Yan Ling; John O'Gorman; Fang Qian; Mahin Arastu; Mingwei Li; Sowmya Chollate; Melanie S Brennan; Omar Quintero-Monzon; Robert H Scannevin; H Moore Arnold; Thomas Engber; Kenneth Rhodes; James Ferrero; Yaming Hang; Alvydas Mikulskis; Jan Grimm; Christoph Hock; Roger M Nitsch; Alfred Sandrock
Journal:  Nature       Date:  2016-09-01       Impact factor: 49.962

4.  Amyloid-Beta Solubility in the Treatment of Alzheimer's Disease.

Authors:  M Paul Murphy
Journal:  N Engl J Med       Date:  2018-01-25       Impact factor: 91.245

  4 in total
  1 in total

1.  A Multifunctional Chemical Agent as an Attenuator of Amyloid Burden and Neuroinflammation in Alzheimer's Disease.

Authors:  Hong-Jun Cho; Anuj K Sharma; Ying Zhang; Michael L Gross; Liviu M Mirica
Journal:  ACS Chem Neurosci       Date:  2020-05-04       Impact factor: 4.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.